

Silverlon® Performance in a Surgical Dressing



Silverlon® dressings provide visible results.

Performance 01

With Silverlon®, you can reference multiple robust, peer-reviewed clinical studies across multiple specialties.



Patient 1: 58 Year old female
Silverlon® dressing / 2 days post-op
Total Hip Arthroplasty

Power 02

Silverlon® Wound Dressings contain more metallic silver than any other dressing.



Patient 2: 53 Year old female with diabetes
Silverlon® dressing / 2 days post-op
Total Hip Arthroplasty

Speed 03

Silverlon® produces a broad-spectrum antimicrobial effect that rapidly kills microorganisms, eradicating MRSA in as little as 4 hours and keeps working for up to 7 days.




Patient 3: 69 Year old female with diabetes
Silverlon® dressing / 14 days post-op
Total Knee Arthroplasty

Silverlon® has an antimicrobial effect within 2 hours against MRSA in the dressing, with eradication in 4 hours.

In vitro test data

SILVERLON® MRSA and Pseudomonas kill rate



*Citation: 510(k) K122817, page 174 of 379.

Time and CFU/ml

Bacterial species		0.0 Hr	0.5 Hr	1.0 Hr	2.0 Hr	4.0 Hr	6.0 Hr	24.0 Hr
Staphylococcus aureus	MRSA ATCC 33591	8,250,000	2,600,000	270,000	500	0	0	0
Pseudomonas aeruginosa	ATCC 9027	9,000,000	4,000,000	0	0	0	0	0



Surgical site infections are a critical problem.

In a Cleveland Clinic study¹ **75%** of all orthopaedic readmissions were for infections and wound complications. Average additional hospital stay 4.9 days

In a Mayo Clinic study,² **32%** of hip arthroplasty studies received post-op antibiotics (oral or IV)

In a Duke Infection Control Outreach Network study,³ the average cost to treat a MRSA infection across 7 U.S. hospitals was **\$61,000**

What makes Silverlon® dressings unique?

Sustained release 01

Deliverable silver ions 02

No staining 03

Silverlon® silver plated nylon technology offers many unique advantages over other silver dressings.



Silverlon® Surface

Silverlon® Magnified

Silverlon® dressings contain more metallic silver than other silver dressings

Proprietary Name	Ag Content mg/100 cm ²
SILVERLON®	546
Askina® Calgitrol® Ag+	141
ACTICOAT [◇]	104
Contreet Foam	85
Contreet	32
AQUACEL® Ag	8.3
SilvaSorb®	5.3
ACTISORB™ Silver 220	2.7

ACTICOAT[◇] is a registered trademark of Smith+Nephew
 Askina® Calgitrol® Ag+ is a registered trademark of B. Braun
 AQUACEL® Ag is a registered trademark of ConvaTec Inc.
 SilvaSorb® is a registered trademark of Virchow Biotech, Inc.
 ACTISORB™ is a trademark of Medical Action Industries, Inc.

Other “Silver” dressings

Silver impregnated dressings

May have as little as 1/50th as much silver as Silverlon® | Silver layer may not be in direct contact with the wounded tissue. | Typically supported by in vitro data only.

Silver nanocrystalline dressings

Typically 1/5th the silver of Silverlon®⁴ | Staining and stinging can occur

- 1 Mesko, Nathan W.; Kovacevic, David; Bachmann, Keith; Trihas, Deana; Lograsso, Mary Ellen; Froimson, Mark I. Thirty Day Orthopedic and Rheumatologic Re-Admissions: Retrospective Analysis at a Tertiary Care Medical Center. Presented at the Mid-America Orthopaedic Association 30th Annual Meeting 2012, Bonita Springs, FL
- 2 Novais, Eduardo H.; Sierra, Rafael J.; Potter, G. David; Trousdale, Robert T. Higher Complication Rate in Obese Than Non-Obese Patients After Periacetabular Osteotomy Presented at the Mid-America Orthopaedic Association 30th Annual Meeting 2012, Bonita Springs, FL
- 3 Anderson, Deverick J.; Kay, Keith S.; Chen, Luke F.; Choi, Yong; Sloan, Richard; Sexton, Daniel J. Clinical and Financial Outcomes Due to Methicillin-Resistant Staphylococcus Aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study PLoS One, Volume 4:12, December 2009
- 4 Steve Thomas PhD. MRSA (Methicillin-Resistant Staphylococcus Aureus) and The Use of Silver Dressings: Overcoming Bacterial Resistance, World Wide Wounds. Nov. 2004, Revision: 1.1



Multiple clinical studies

Independent, peer-reviewed and published clinical studies suggest Silverlon® Island Dressings can be an important element in wound care and control of wound bacteria within the dressing may help reduce the risk of wound infection.

- **Use of Silver Nylon Dressing Following Total Hip and Knee Arthroplasty Decreases the Postoperative Infection Rate**

Ashley J. Tisosky MD, Otatade Iyoha-Bello BSc, Nicholas Demosthenes BA, Giovanni Quimbayo MD, Tara Coreanu BSc, Ayesha Abdeen MD FRCS
Harvard Combined Orthopaedic Residency Program, Massachusetts General Hospital, Boston, MA, USA

- **The Use of Silver Nylon in Preventing Surgical Site Infections Following Colon and Rectal Surgery**

Beth Krieger MD, Donald M. Davis MD, Jaime E. Sanchez MD, James J. Mateka, Valentine N Nfonso MD, Jared C. Frattini MD, Jorge E. Marcet MD
St. John's Health Center, Springfield, MO, USA

- **Reduction in Central Line-Associated Bloodstream Infections Correlated With the Introduction of a Novel Silver-Plated Dressing for Central Venous Catheters and Maintained for 6 Years**

Rachel Karlinski PhD, Elia Charbel Abboud MD, Peggy Thompson BSN CIC FAPIC, Asa Z. Oxner MD, John T. Sinnott, MD FACP, Jorge E. Marcet MD
FACS FASCRS Tampa General Hospital, Tampa, FL, USA

- **A Clinical Trial to Investigate the Effect of Silver Dressings on Mediastinitis Rates in Postoperative Cardiac Sternotomy incisions**

Roger Huckfeldt MD FACS, Clyde Redmond MD, Debbie Mikkelsen BSM, Philip J. Finley MS, Cindy Lowe BS CCRP, Jennifer Robertson RN St. John's
Regional Health Center, Springfield, MO, USA

- **Do Silver-Impregnated Dressings Limit Infections After Lumbar Laminectomy with Instrumented Fusion?**

Nancy E. Epstein MD, Albert Einstein college of Medicine, Bronx, NY, USA

Please note that these studies may involve findings that exceed the claims currently cleared by the U.S. FDA for the product. Argentum Medical, LLC is not intending to make performance claims about its product. The intent is to disseminate the scientific literature on these products. We encourage you to read these studies to understand the strengths and limitations of the data. The actual intended use statements cleared by the U.S. FDA for these products are set forth below.

Silverlon® dressings have been tested in vitro and found effective against microorganisms such as: Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus (VRE), Staphylococcus epidermidis, Escherichia Coli (E. coli), Shigella sonnei, Pseudomonas aeruginosa, Pseudomonas cepacia, Pseudomonas maltophilia, Acinetobacter calcoaceticus, Enterobacter cloacae, Salmonella typhimurium, Salmonella typhi, Enterococcus sp., Serratia marcescens, Listeria monocytogenes, Enterobacter cloacae, Staphylococcus, Streptococcus, Group B Streptococcus, Candida albicans, and Aspergillus niger



Indications

Silverlon® Island Dressings are professional wound dressings intended for the local management of:

- Donor and graft site wounds
- Diabetic, pressure and venous ulcers
- Surgical wounds
- Infected wounds*

*Silverlon® Island Dressings may be used on those infected wound types listed above. Where used on infected wounds, the infection should be treated as per local clinical protocol. Silverlon® Island Dressings are indicated for a total duration of contact (i.e. where treatment involves consecutive application of individual dressings) not to exceed 30 days.

Contraindications

- Silverlon® Island Dressings are latex free.
- Avoid using Silverlon® Island Dressings on patients with known sensitivity to silver or nylon.
- Silverlon® Island Dressings are not intended for use on 3rd degree burns.



Ordering Information

Silverlon® Surgical Island Dressings

Product and Catalogue No.	Size
ID-23	5 x 8 cm
ID-34	8 x 10 cm
ID-44	10 x 10 cm
ID-46	10 x 15 cm
ID-48	10 x 20 cm
ID-410	10 x 25 cm
ID-412	10 x 30 cm
ID-414	10 x 36 cm
ID-66	15 x 15 cm

To learn more about Silverlon® solutions, please contact:



G&N
Maydwell Avenue, Stane Street,
Slinfold, Horsham, West Sussex RH13 0GN
Tel: +44 (0) 1403 799190
Email: sales@gandn.com
www.gandn.com